Loading the session
Loading the session
Loading instrument
$61.50
−0.21%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:43 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +18.1% (SPY −1.6%, XLV +13.5%). 3 months: +23.6% (SPY −0.4%, XLV +15.5%). 1 year: +82.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TGTX, SPY and XLV · as of 4 Nov 2026
Closed at $61.63 on 4 Nov 2026: 3.1% below the 52-week high of $63.60 (2 Nov 2026) and 130.3% above the low of $26.76 (12 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
29.6M shares were sold short at the 15 Oct 2026 settlement, 19.3% of the 153.1M shares outstanding; covering them would take 18.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $61.63 was 10.7% above its 50-day average ($55.66) and 39.3% above its 200-day average ($44.26). It has closed above the 200-day for 152 sessions, since 31 Mar 2026. The 50-day average crossed above the 200-day on 29 Apr 2026, 131 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
August 1, 2023
−49.30%November 10, 2022
+63.37%January 27, 2022
−40.50%